Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 18,757 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumors
Interventions
KN035
Drug
Lead sponsor
3D Medicines (Sichuan) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Lafayette, Indiana • San Antonio, Texas
Terminated Phase 1 Interventional Results available

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

NCT05147350
Conditions
Advanced Solid Tumor
Interventions
RP-6306 (oral PKMYT1 inhibitor)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 2 more
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme
Interventions
Ascorbate, Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Cancer
Interventions
EM-1421
Drug
Lead sponsor
Erimos Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • The Bronx, New York • Nashville, Tennessee
Conditions
Neoplasm, Cancer, Tumors
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more
Conditions
Pain, Prostate Cancer
Interventions
filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy
Biological · Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Los Angeles, California • Vero Beach, Florida • Great Neck, New York + 3 more
Conditions
Healthy Participants Study
Interventions
AZD0292, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
Interventions
Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Kansas City, Kansas • The Bronx, New York
Conditions
Relapsed or Refractory T Cell Lymphoma
Interventions
ONO-4685
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 17 more
Conditions
Hepatitis C, Pregnancy
Interventions
ledipasvir/sofosbuvir
Drug
Lead sponsor
Catherine Chappell
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Metastatic Cancer
Interventions
temozolomide, vinorelbine tartrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer

NCT00095589
Conditions
Bladder Cancer
Interventions
loss of heterozygosity analysis, microarray analysis, microsatellite instability analysis, cytology specimen collection procedure, laboratory biomarker analysis, computed tomography, cystoscopy
Genetic · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years to 120 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Chicago, Illinois + 8 more
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
oblimersen sodium, cisplatin, fluorouracil
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Type 2 Diabetes
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fort Myers, Florida • Sarasota, Florida • River Forest, Illinois + 4 more
Conditions
T Cell Lymphoma
Interventions
CTX130
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Duarte, California • Stanford, California • New Haven, Connecticut + 5 more
Conditions
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
Interventions
Avapritinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Atlanta, Georgia + 6 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, fluorouracil, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumors
Interventions
ASP5878
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Orange, California • New York, New York • Cleveland, Ohio + 3 more
Conditions
Platelet Inhibition
Interventions
PN400, ASA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Brain Tumor, Glioblastoma
Interventions
Vorinostst/Bevacizumab/Temozolomide
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions
Darlifarnib, Cabozantinib, Adagrasib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas